|
1
|
Zong G, Xu Z, Zhang S, Shen Y, Qiu H, Zhu
G, He S, Tao T and Chen X: CD109 mediates cell survival in
hepatocellular carcinoma cells. Dig Dis Sci. 61:2303–2314. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mansourian PG, Yoneda M, Rao Krishna M,
Martinez FJ, Thomas E and Schiff ER: Effects of statins on the risk
of hepatocellular carcinoma. Gastroenterol Hepatol (N Y).
10:417–426. 2014.PubMed/NCBI
|
|
3
|
Kew MC: Hepatocellular carcinoma in
developing countries: Prevention, diagnosis and treatment. World J
Hepatol. 4:99–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang S, Yue M, Shu R, Cheng H and Hu P:
Recent advances in the management of hepatocellular carcinoma. J
BUON. 21:307–311. 2016.PubMed/NCBI
|
|
5
|
Harlan LC, Parsons HM, Wiggins CL, Stevens
JL and Patt YZ: Treatment of hepatocellular carcinoma in the
community: Disparities in standard therapy. Liver Cancer. 4:70–83.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuen MF, Ahn SH, Chen DS, Chen PJ,
Dusheiko GM, Hou JL, Maddrey WC, Mizokami M, Seto WK, Zoulim F and
Lai CL: Chronic Hepatitis B virus infection: Disease revisit and
management recommendations. J Clin Gastroenterol. 50:286–294. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parker JL, Mindell JA and Newstead S:
Thermodynamic evidence for a dual transport mechanism in a POT
peptide transporter. Elife. 3:2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jensen JM, Simonsen FC, Mastali A, Hald H,
Lillebro I, Diness F, Olsen L and Mirza O: Biophysical
characterization of the proton-coupled oligopeptide transporter
YjdL. Peptides. 38:89–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gong Y, Wu X, Wang T, Zhao J, Liu X, Yao
Z, Zhang Q and Jian X: Targeting PEPT1: A novel strategy to improve
the antitumor efficacy of Doxorubicin in human hepatocellular
carcinoma therapy. Oncotarget. 15:40454–40468. 2017.
|
|
10
|
Kumar KK, Karnati S, Reddy MB and
Chandramouli R: Caco-2 cell lines in drug discovery-an updated
perspective. J Basic Clin Pharm. 1:63–69. 2010.PubMed/NCBI
|
|
11
|
Gonzalez DE, Covitz KM, Sadée W and Mrsny
RJ: An oligopeptide transporter is expressed at high levels in the
pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res.
58:519–525. 1998.PubMed/NCBI
|
|
12
|
Namikawa T, Yatabe T, Inoue K, Shuin T and
Hanazaki K: Clinical applications of 5-aminolevulinic acid-mediated
fluorescence for gastric cancer. World J Gastroenterol.
21:8769–8775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tai W, Chen Z and Cheng K: Expression
profile and functional activity of peptide transporters in prostate
cancer cells. Mol Pharm. 10:477–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun D, Tan F, Fang D, Wang Y, Zeng S and
Jiang H: Expression of proton-coupled oligopeptide transporter
(POTs) in prostate of mice and patients with benign prostatic
hyperplasia (BPH) and prostate cancer (PCa). Prostate. 73:287–295.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakanishi T, Tamai I, Sai Y, Sasaki T and
Tsuji A: Carrier-mediated transport of oligopeptides in the human
fibrosarcoma cell line HT1080. Cancer Res. 57:4118–4122.
1997.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gong XL and Qin SK: Progress in systemic
therapy of advanced hepatocellular carcinoma. World J
Gastroenterol. 22:6582–6594. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slotta JE, Kollmar O, Ellenrieder V,
Ghadimi BM and Homayounfar K: Hepatocellular carcinoma: Surgeon's
view on latest findings and future perspectives. World J Hepatol.
7:1168–1183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang CH, Wey KC, Mo LR, Chang KK, Lin RC
and Kuo JJ: Current trends and recent advances in diagnosis,
therapy and prevention of hepatocellular carcinoma. Asian Pac J
Cancer Prev. 16:3595–3604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sahara S, Kawai N, Sato M, Tanaka T, Ikoma
A, Nakata K, Sanda H, Minamiguchi H, Nakai M, Shirai S and Sonomura
T: Prospective evaluation of transcatheter arterial
chemoembolization (TACE) with multiple anti-cancer drugs
(epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with
TACE with epirubicin for treatment of hepatocellular carcinoma.
Cardiovasc Intervent Radiol. 35:1363–1371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paul SB and Sharma H: Role of
transcatheter intra-arterial therapies for hepatocellular
carcinoma. J Clin Exp Hepatol. 4:(Suppl 3). S112–S121. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keating GM: Sorafenib: A Review in
hepatocellular carcinoma. Target Oncol. 12:243–253. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deng GL, Zeng S and Shen H: Chemotherapy
and target therapy for hepatocellular carcinoma: New advances and
challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng C, Ma C, Bai E, Yang K and Xu R:
Transferrin and cell-penetrating peptide dual-functioned liposome
for targeted drug delivery to glioma. Int J Clin Exp Med.
8:1658–1668. 2015.PubMed/NCBI
|
|
25
|
Meyers JD, Cheng Y, Broome AM, Agnes RS,
Schluchter MD, Margevicius S, Wang X, Kenney ME, Burda C and
Basilion JP: Peptide-targeted gold nanoparticles for photodynamic
therapy of brain cancer. Part Part Syst Charact. 32:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maiolino S, Russo A, Pagliara V, Conte C,
Ungaro F, Russo G and Quaglia F: Biodegradable nanoparticles
sequentially decorated with Polyethyleneimine and Hyaluronan for
the targeted delivery of docetaxel to airway cancer cells. J
Nanobiotechnology. 13:292015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tai W, Shukla RS, Qin B, Li B and Cheng K:
Development of a peptide-drug conjugate for prostate cancer
therapy. Mol Pharm. 8:901–912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakanishi T, Tamai I, Takaki A and Tsuji
A: Cancer cell-targeted drug delivery utilizing oligopeptide
transport activity. Int J Cancer. 88:274–280. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nielsen CU and Brodin B: Di/tri-peptide
transporters as drug delivery targets: Regulation of transport
under physiological and patho-physiological conditions. Curr Drug
Targets. 4:373–388. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun D, Wang Y, Tan F, Fang D, Hu Y, Smith
DE and Jiang H: Functional and molecular expression of the
proton-coupled oligopeptide transporters in spleen and macrophages
from mouse and human. Mol Pharm. 10:1409–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Daniel H and Kottra G: The proton
oligopeptide cotransporter family SLC15 in physiology and
pharmacology. Pflugers Arch. 447:610–618. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ganapathy ME, Huang W, Wang H, Ganapathy V
and Leibach FH: Valacyclovir: A substrate for the intestinal and
renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res
Commun. 246:470–475. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sugawara M, Huang W, Fei YJ, Leibach FH,
Ganapathy V and Ganapathy ME: Transport of valganciclovir, a
ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J
Pharm Sci. 89:781–789. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rubio-Aliaga I and Daniel H: Peptide
transporters and their roles in physiological processes and drug
disposition. Xenobiotica. 38:1022–1042. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu Y, Xie Y, Keep RF and Smith DE:
Divergent developmental expression and function of the
proton-coupled oligopeptide transporters PepT2 and PhT1 in regional
brain slices of mouse and rat. J Neurochem. 129:955–965. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Doki S, Kato HE, Solcan N, Iwaki M, Koyama
M, Hattori M, Iwase N, Tsukazaki T, Sugita Y, Kandori H, et al:
Structural basis for dynamic mechanism of proton-coupled symport by
the peptide transporter POT. Proc Natl Acad Sci USA.
110:11343–11348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu Y, Xie Y, Wang Y, Chen X and Smith DE:
Development and characterization of a novel mouse line humanized
for the intestinal peptide transporter PEPT1. Mol Pharm.
11:3737–3746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang B, Hu Y and Smith DE: Impact of
peptide transporter 1 on the intestinal absorption and
pharmacokinetics of valacyclovir after oral dose escalation in
wild-type and PepT1 knockout mice. Drug Metab Dispos. 41:1867–1874.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Boll M, Markovich D, Weber WM, Korte H,
Daniel H and Murer H: Expression cloning of a cDNA from rabbit
small intestine related to proton-coupled transport of peptides,
beta-lactam antibiotics and ACE-inhibitors. Pflugers Arch.
429:146–149. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hsu CP, Hilfinger JM, Walter E, Merkle HP,
Roessler BJ and Amidon GL: Overexpression of human intestinal
oligopeptide transporter in mammalian cells via adenoviral
transduction. Pharm Res. 15:1376–1381. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Terada T and Inui K: Peptide transporters:
Structure, function, regulation and application for drug delivery.
Curr Drug Metab. 5:85–94. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Luckner P and Brandsch M: Interaction of
31 beta-lactam antibiotics with the H+/peptide symporter PEPT2:
Analysis of affinity constants and comparison with PEPT1. Eur J
Pharm Biopharm. 59:17–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Newstead S: Molecular insights into proton
coupled peptide transport in the PTR family of oligopeptide
transporters. Biochim Biophys Acta. 1850:488–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jappar D, Wu SP, Hu Y and Smith DE:
Significance and regional dependency of peptide transporter (PEPT)
1 in the intestinal permeability of glycylsarcosine: In situ
single-pass perfusion studies in wild-type and Pept1 knockout mice.
Drug Metab Dispos. 38:1740–1746. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mrsny RJ: Oligopeptide transporters as
putative therapeutic targets for cancer cells. Pharm Res.
15:816–818. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Landowski CP, Vig BS, Song X and Amidon
GL: Targeted delivery to PEPT1-overexpressing cells: Acidic, basic
and secondary floxuridine amino acid ester prodrugs. Mol Cancer
Ther. 4:659–467. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mitsuoka K, Kato Y, Miyoshi S, Murakami Y,
Hiraiwa M, Kubo Y, Nishimura S and Tsuji A: Inhibition of
oligopeptide transporter suppress growth of human pancreatic cancer
cells. Eur J Pharm Sci. 40:202–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gonzalez DE, Covitz KM, Sadée W and Mrsny
RJ: An oligopeptide transporter is expressed at high levels in the
pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res.
58:519–525. 1998.PubMed/NCBI
|
|
49
|
Inoue M, Terada T, Okuda M and Inui K:
Regulation of human peptide transporter 1 (PEPT1) in gastric cancer
cells by anticancer drugs. Cancer Lett. 230:72–80. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Buyse M, Berlioz F, Guilmeau S, Tsocas A,
Voisin T, Péranzi G, Merlin D, Laburthe M, Lewin MJ, Rozé C and
Bado A: PepT1-mediated epithelial transport of dipeptides and
cephalexin is enhanced by luminal leptin in the small intestine. J
Clin Invest. 108:1483–1494. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Han HK, Oh DM and Amidon GL: Cellular
uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1
cells overexpressing a human peptide transporter. Pharm Res.
15:1382–1386. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen M, Singh A, Xiao F, Dringenberg U,
Wang J, Engelhardt R, Yeruva S, Rubio-Aliaga I, Nässl AM, Kottra G,
et al: Gene ablation for PEPT1 in mice abolishes the effects of
dipeptides on small intestinal fluid absorption, short-circuit
current, and intracellular pH. Am J Physiol Gastrointest Liver
Physiol. 299:G265–G274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Verri T, Kottra G, Romano A, Tiso N, Peric
M, Maffia M, Boll M, Argenton F, Daniel H and Storelli C: Molecular
and functional characterisation of the zebrafish (Danio rerio)
PEPT1-type peptide transporter. FEBS Lett. 549:115–122. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Agu R, Cowley E, Shao D, Macdonald C,
Kirkpatrick D, Renton K and Massoud E: Proton-coupled oligopeptide
transporter (POT) family expression in human nasal epithelium and
their drug transport potential. Mol Pharm. 8:664–672. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Berthelsen R, Nielsen CU and Brodin B:
Basolateral glycylsarcosine (Gly-Sar) transport in Caco-2 cell
monolayers is pH dependent. J Pharm Pharmacol. 65:970–979. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dalmasso G, Nguyen HT, Charrier-Hisamuddin
L, Yan Y, Laroui H, Demoulin B, Sitaraman SV and Merlin D: PepT1
mediates transport of the proinflammatory bacterial tripeptide
L-Ala-{gamma}-D-Glu-meso-DAP in intestinal epithelial cells. Am J
Physiol Gastrointest Liver Physiol. 299:G687–G696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Terada T, Sawada K, Ito T, Saito H,
Hashimoto Y and Inui K: Functional expression of novel peptide
transporter in renal basolateral membranes. Am J Physiol Renal
Physiol. 279:F851–F857. 2000.PubMed/NCBI
|
|
58
|
Tan S, Wu T, Zhang D and Zhang Z: Cell or
cell membrane-based drug delivery systems. Theranostics. 5:863–881.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Foltz M, Meyer A, Theis S, Demuth HU and
Daniel H: A rapid in vitro screening for delivery of
peptide-derived peptidase inhibitors as potential drug candidates
via epithelial peptide transporters. J Pharmacol Exp Ther.
310:695–702. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang S, Placzek WJ, Stebbins JL, Mitra S,
Noberini R, Koolpe M, Zhang Z, Dahl R, Pasquale EB and Pellecchia
M: Novel targeted system to deliver chemotherapeutic drugs to
EphA2-expressing cancer cells. J Med Chem. 55:2427–2436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rubio-Aliaga I and Daniel H: Mammalian
peptide transporters as targets for drug delivery. Trends Pharmacol
Sci. 23:434–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
